What is it about?
Research work involves developing a stable nanoemulsion of a potent hepatoprotective agent 'silymarin' and further assessing its anti cancer activity on HEPG2 cancer cell lines.
Featured Image
Why is it important?
Liver cancer is the sixth most common cancer in the world, with 782,000 new cases diagnosed in 2012. Developing a stable and effective dosage form using novel nanotechnology approaches is necessary to target cancer cells without harming normal cells.
Read the Original
This page is a summary of: Silymarin nanoemulsion against human hepatocellular carcinoma: development and optimization, Artificial Cells Nanomedicine and Biotechnology, May 2017, Taylor & Francis,
DOI: 10.1080/21691401.2017.1324465.
You can read the full text:
Contributors
The following have contributed to this page
